Javelin Pharmaceuticals, Inc., together with its subsidiaries, engages in the research, development, and commercialization of products for pain relief in the United States. Its product candidates include Dyloject, which is in Phase III development stage for the treatment of post-operative pain in the United States, as well as in MAA Review stage for the treatment of acute forms of pain, including renal colic, exacerbations of osteo and rheumatoid arthritis, acute back pain, acute gout, acute trauma, and pain associated with fractures in Europe. The company's products also include Rylomine, an intranasal formulation of morphine that is in Phase III development stage for the treatment of acute moderate-to-severe pain and breakthrough pain in the United States and Europe; and PMI-150, a proprietary nasal formulation of ketamine that is under registration studies for the treatment of acute moderate-to-severe pain, including breakthrough pain in the United States. Its products also focus on treating various pain disorders, including episodic moderate-to-severe pain associated with breakthrough cancer pain; and post-trauma pain, such as orthopedic injury pain, procedural pain, and burn pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.